GSAP: A Promising Drug Target / Biomarker (G54103)

Target Name: GSAP

NCBI ID: G54103

GSAP

GSAP: A Promising Drug Target / Biomarker

G protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. One of the most promising drug targets in the GPCRs is GABA-zucupsin (GSAP), which is a GPCR that plays a role in the regulation of neurotransmitter release and has been implicated in various neurological disorders.

GSAP: Structure and Function

GSAP is a 7-transmembrane protein that is characterized by a long N-terminal cytoplasmic region, a transmembrane region, and an C-terminal region that includes a G protein-coupled receptor (GPCR) domain. The GPCR domain is composed of a catalytic 伪-helices and a 尾-sheet that is responsible for the formation of the ion-channel pore that allows for the exchange of positive and negative charges in the membrane.

GSAP is a GPCR that is expressed in various tissues, including brain, heart, and pancreas, and has been shown to play a role in the regulation of neurotransmitter release. For example, GSAP has been shown to be involved in the regulation of dopamine (DA) release in the brain, where it is thought to play a role in the control of movement and motivation.

GSAP has also been shown to be involved in the regulation of neurotransmitter release in response to changes in the environment. For example, GSAP has been shown to play a role in the regulation of serotonin (5-HT) release in response to changes in light intensity, which is thought to play a role in the regulation of mood and emotion.

Drug Targeting

GSAP is a drug target of great interest due to its involvement in the regulation of neurotransmitter release. Several compounds have been shown to be potent inhibitors of GSAP, with a focus on compounds that can modulate the activity of GSAP in a specific manner.

One of the most promising compounds that has been shown to be a potent inhibitor of GSAP is a small molecule called LY272119. LY272119 is a potent inhibitor of GSAP and has been shown to be effective in a range of behavioral and physiological tests, including the regulation of neurotransmitter release.

Another compound that has shown promise as a potential GSAP inhibitor is a peptide called P1201. P1201 is a short peptide that contains a single amino acid, which is thought to modulate the activity of GSAP. Preclinical studies have shown that P1201 is a potent inhibitor of GSAP and has the potential to be a useful drug for the treatment of various neurological disorders.

GSAP as a Biomarker

In addition to its potential as a drug target, GSAP is also a potential biomarker for various neurological disorders. The regulation of neurotransmitter release is a critical aspect of brain function, and changes in neurotransmitter release can be indicative of underlying neurological disorders.

GSAP has been shown to be involved in the regulation of neurotransmitter release, which suggests that it may be a useful biomarker for the diagnosis and treatment of disorders that are characterized by changes in neurotransmitter release. For example, GSAP has been shown to be involved in the regulation of dopamine release in the brain, which is thought to play a role in the treatment of Parkinson's disease.

In addition to its potential as a drug target and biomarker, GSAP is also of interest as a potential therapeutic approach for the treatment of various neurological disorders. The regulation of neurotransmitter release is a critical aspect of brain function, and disorders characterized by changes in neurotransmitter release may be treatable by modulating the activity

Protein Name: Gamma-secretase Activating Protein

Functions: Regulator of gamma-secretase activity, which specifically activates the production of amyloid-beta protein (amyloid-beta protein 40 and amyloid-beta protein 42), without affecting the cleavage of other gamma-secretase targets such has Notch. The gamma-secretase complex is an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). Specifically promotes the gamma-cleavage of APP CTF-alpha (also named APP-CTF) by the gamma-secretase complex to generate amyloid-beta, while it reduces the epsilon-cleavage of APP CTF-alpha, leading to a low production of AICD

The "GSAP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSAP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets